4-羟基-N-甲基丁烷酰胺 | 37941-69-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-羟基-N-甲基丁烷酰胺
• 中文别名: 4-羟基-N-甲基丁酰胺
• 英文名称: γ-hydroxybutyric acid monomethylamide
• 英文别名: 4-hydroxy-N-methyl-butanamide；4-hydroxy-N-methylbutanamide；N-methyl-4-hydroxybutanamide；N-methyl-4-hydroxybutyramide；N-methyl-γ-hydroxybutyramide；N-methyl 4-hydroxybutyramide
• CAS: 37941-69-8
• 化学式: C₅H₁₁NO₂
• 分子量: 117.148
• InChiKey: DLKOPXVSDZXMRM-UHFFFAOYSA-N

物化性质

• 熔点：
  32-34 °C
• 沸点：
  100-110 °C(Press: 1 Torr)
• 密度：
  1.023±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090
• 储存条件：
  存储条件：2-8°C，需密封并保持干燥。

反应信息

• 作为反应物：
  描述：

  4-羟基-N-甲基丁烷酰胺 在 吡啶 、 ammonium hydroxide 、 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 26.5h， 生成 1-甲基吡咯烷
  参考文献：
  名称：

  The 4-[N-Methyl-N-(2,2,2-trifluoroacetyl)amino]butyl Group as an Alternative to the 2-Cyanoethyl Group for Phosphate Protection in the Synthesis of Oligodeoxyribonucleotides

  摘要：

  The 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl group for phosphate protection in the synthesis of oligodeoxyribonucleotides has been developed to completely prevent nucleobase alkylation by acrylonitrile that could potentially occur upon deprotection of the traditional 2-cyanoethyl phosphate protecting group. The properties of this new phosphate protecting group were evaluated using the model phosphotriester 9. The mechanism of phosphate deprotection was studied by treating 9 with concentrated NH4OH. NMR analysis,of the deprotection reaction demonstrated that cleavage of the N-trifluoroacetyl group is rate-limiting. The resulting phosphotriester intermediate 13 was also shown to undergo rapid cyclodeesterification to produce O,O-diethyl phosphate 15 and N-methylpyrrolidine -16 (Scheme 2). Given the facile removal of the 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl phosphate protecting group under mild basic conditions, its utilization in oligonucleotide synthesis began with the preparation of the deoxyribonucleoside phosphoramidites 4a-d (Scheme 3). The coupling efficiency of 4a-d and conventional a-cyanoethyl deoxyribonucleoside phosphoramidites 24a-d was then compared in the solid-phase synthesis of the 20-mer d(ATCCGTAGCTAAGGTCATGC). As previously observed in the deprotection of 9, the 4-[N-methyl,N-(2,2,2-trifluoroacetyl)amino]butyl phosphate protecting groups were easily and completely removed from the oligonucleotide by using either concentrated NH4OH or pressurized ammonia gas. Analysis of the deprotected oligomer by polyacrylamide gel electrophoresis (Figure 3) indicated that the phosphoramidites 4a-d are as efficient as the 2-cyanoethyl phosphoramidites 24a-d in the synthesis of the 20-mer. Furthermore, following digestion of the crude 20-mer by snake venom phosphodiesterase and bacterial alkaline phosphatase, HPLC analysis showed complete hydrolysis to individual nucleosides and no detectable nucleobase modification.

  DOI：

  10.1021/jo990835w
• 作为产物：
  描述：

  N-甲基丁二酰胺 在 C₄₆H₄₂N₂P₂Ru 、 potassium tert-butylate 、 氢气 作用下， 以 四氢呋喃 为溶剂， 30.0 ℃ 、405.33 kPa 条件下， 反应 3.0h， 以100%的产率得到4-羟基-N-甲基丁烷酰胺
  参考文献：
  名称：

  通过对映选择性单氢化反应去对称化中环酰亚胺

  摘要：

  使用反式-[Ru((R)-BINAP)(H)(2)((R,R)-dpen)] 和相关化合物，将内消旋酰亚胺单氢化以形成 88-97% ee 的相应羟基内酰胺THF 中碱的催化剂。氢化以高对映基团和化学选择性进行，它是一种去对称化反应，在一个反应​​中形成多达五个立体中心。羟基内酰胺转化为相应的亚胺离子，然后加入茚将立体中心的数量从 5 扩展到 7。

  DOI：

  10.1021/ja105783u

文献信息

• [EN] VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES<br/>[FR] DÉRIVÉS DE VALSARTAN PORTANT DES DONNEURS D'OXYDE D'AZOTE DANS LE TRAITEMENT DE MALADIES VASCULAIRES ET MÉTABOLIQUES
  申请人：CARDIOLYNX AG

  公开号：WO2011131613A1

  公开（公告）日：2011-10-27

  Nitrate esters and diazeniumdiolate derivatives of valsartanamide are described. They have valuable properties in the treatment of vascular and metabolic diseases.

  硝酸酯和缬沙坦胺的重氮二醇酯衍生物被描述。它们在治疗血管和代谢性疾病方面具有宝贵的特性。
• [EN] FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY<br/>[FR] DÉRIVÉS DE [1,2,4]THIADIAZINE FUSIONNÉS AGISSANT EN TANT QU'INHIBITEURS DE KAT DE LA FAMILLE DES MYST
  申请人：CTXT PTY LTD

  公开号：WO2019043139A1

  公开（公告）日：2019-03-07

  A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

  一种化合物的化学式（I）：抑制MYST家族中一个或多个KATs的活性，即TIP60、KAT6B、MOZ、HBO1和MOF。
• A Mild and Facile Synthesis of Cyclic Imides using Pyridinium Chlorochromate
  作者：Yanyan Yang、Ge Wang、Xiaohui Cao、Xilong Yan、Ligong Chen

  DOI：10.3184/174751911x13202290249578

  日期：2011.11

  A mild and facile synthetic method of cyclic imides is presented. These compounds are widely used in the synthesis of novel medical, polymeric, photonic and electronic materials. Compared with traditional syntheses, the method reported has several advantages including mild conditions, simplified work-up and low cost.

  本文介绍了一种温和、简便的环状亚胺合成方法。这些化合物被广泛用于合成新型医用、聚合、光子和电子材料。与传统合成方法相比，该方法具有条件温和、操作简单和成本低廉等优点。
• A Study on the Intramolecular Mitsunobu Reaction of<i>N</i>⁶-(ω-Hydroxyalkyl)adenines
  作者：Naděžda Šimůnková、Tomáš Tobrman、Václav Eigner、Dalimil Dvořák

  DOI：10.1002/jhet.2982

  日期：2017.11

  The cyclization of N6‐(ω‐hydroxyalkyl)adenines with a N6H‐group leads to N6,N1 ring closure regardless of the method of the cyclization that was used. Five‐membered to eight‐membered rings were obtained using NBS/PPh3; however, under Mitsunobu conditions, the eight‐membered fused purine was not formed. Surprisingly, the cyclization of N6‐methyl‐N6‐(4‐hydroxybutyl)adenine only leads to N6,N7 ring closure

  不管使用哪种环化方法，具有N 6 H-基团的N 6-（ω-羟烷基）腺嘌呤的环化都会导致N 6，N1闭环。使用NBS / PPh 3获得了五元至八元环。但是，在光延条件下，没有形成八元融合嘌呤。出人意料的是，使用这两种方法，N 6-甲基-N 6-（4-羟基丁基）腺嘌呤的环化只会导致N 6，N7闭环。
• PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II
  申请人：Dousson Cyril

  公开号：US20090060866A1

  公开（公告）日：2009-03-05

  Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formula I, II, III, I′, II′, I″, II″, Ia, IIa, or IIIa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本发明提供了磷二嗪聚合酶抑制剂，例如任何式I、II、III、I′、II′、I″、II″、Ia、IIa或IIIa的化合物，包含这些化合物的药物组合物，以及它们的制备方法。还提供了用于治疗宿主中HCV感染的方法。